Your fact-checks will appear here
Remission of type 2 diabetes through various treatments.
Medically proven strategies that can manage and in many cases induce remission of (T2DM) center on substantial and sustained weight loss achieved via intensive lifestyle interventions, , short-term in...
There are legitimate, FDA‑approved treatments for type 2 diabetes that have evidence of producing remission—most strongly metabolic/bariatric surgery and intentional substantial weight loss through st...
Type 2 diabetes is treated with a layered, evidence-based toolkit that begins with lifestyle intervention and metformin and expands to multiple drug classes—GLP‑1 receptor agonists, SGLT2 inhibitors, ...
The claim that dietary supplements can "reverse" type 2 diabetes is not supported by high-quality clinical evidence; randomized trials and major clinical guidelines prioritize behavioral, surgical and...
Randomized‑controlled trials (RCTs) show the strongest, most durable remission signals for metabolic/bariatric surgery, while structured intensive weight‑loss programs and several non‑surgical dietary...
Type 2 diabetes (T2D) can be pushed into remission or markedly better glycemic control by several proven strategies: intensive weight-loss–focused lifestyle programs, metabolic/bariatric surgery, shor...
Randomized trials, pooled analyses and long-term cohort data consistently show bariatric (metabolic) surgery produces higher rates of (T2D) remission and more durable glycemic control than intensive m...
Randomized and controlled clinical trials show that type 2 diabetes (T2D) remission—sustained non‑diabetic glycemia off glucose‑lowering drugs for defined periods—can be achieved by several interventi...
Peer‑reviewed evidence shows that intensive, multicomponent lifestyle interventions can produce in a subset of people—most of the evidence comes from randomized controlled trials, large prevention tri...
Randomized-trial evidence shows that structured intensive lifestyle programs can induce remission of type 2 diabetes in a meaningful minority of participants, GLP‑1 receptor agonists produce larger sh...
Randomized trial evidence and several recent systematic reviews show that clinically meaningful weight loss achieved with GLP‑1 and GLP‑1/GIP agonists is frequently lost after drug withdrawal—with mos...
Younger patients with shorter known diabetes duration, lower baseline HbA1c and a low requirement for glucose‑lowering medications (especially absence of insulin or sulfonylureas) have the highest pro...